Patents Examined by Brian E McDowell
  • Pyridazinones as PARP7 inhibtors
    Patent number: 11691969
    Abstract: The present invention relates to pyridazinones and related compounds having Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 4, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • Compounds active towards nuclear receptors
    Patent number: 11685727
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: June 27, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • MK2 inhibitors and uses thereof
    Patent number: 11680056
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: June 20, 2023
    Assignee: XINTHERA, INC.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
    Patent number: 11673884
    Abstract: Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: June 13, 2023
    Assignee: Foresee Pharmaceuticals Co., Inc.
    Inventors: Wenjin Yang, Kai-Wei Chang
  • Pyrimidines as EGFR inhibitors and methods of treating disorders
    Patent number: 11673882
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: June 13, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Pasi Janne, Hwan Geun Choi, Jaebong Jang
  • Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative
    Patent number: 11667642
    Abstract: Provided is a novel and industrially useful method for producing a 3,6-disubstituted imidazo[1,2-b]pyridazine derivative. The present invention provides a method for producing a 3,6-disubstituted imidazo[1,2-b]pyridazine derivative, which uses 6-fluoroimidazo[1,2-b]pyridazine as a starting material, while using an aromatic substitution reaction that utilizes C—H activation by means of palladium.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 6, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ryoji Koike, Yoshifumi Hachisu, Takafumi Kitawaki, Shohei Shiraishi
  • Crystalline substituted pyrazines as PGI2 receptor agonists
    Patent number: 11655218
    Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2?) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?). A form-II crystal of Compound B, which shows peaks at diffraction angles (2?) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?).
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: May 23, 2023
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventor: Toshio Fujiwara
  • Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof
    Patent number: 11655239
    Abstract: The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 23, 2023
    Assignee: Shanghai Institute Of Material Medica, Chinese Academy of Sciences
    Inventors: Bing Xiong, Jia Li, Meiyu Geng, Jingkang Shen, Yi Zang, Jing Ai, Danqi Chen, Qi Wang, Ying Dong, Xia Peng, Yinchun Ji, Qian Tan
  • Organic electroluminescent materials and devices
    Patent number: 11653558
    Abstract: A compound having the formula (LA)mIr(LB)3-m, where LA is and LB is selected from is disclosed. In the formula (LA)mIr(LB)3-m, LA and LB are different; each of X1 to X5 is C—RF or nitrogen; X is selected from O, S, and Se; each R1, R2, RB, RD, RE, and RF is hydrogen or a substituent; R3 is alkyl, cycloalkyl, or a combination thereof; and m is 1 or 2. OLEDs, consumer products, and formulations including the compound are also disclosed.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: May 16, 2023
    Assignee: Universal Display Corporation
    Inventors: Bin Ma, Edward Barron, Alan DeAngelis, Walter Yeager, Zeinab Elshenawy, Harvey Wendt, Ting-Chih Wang, Kwang-Ohk Cheon, Chuanjun Xia
  • 1,3-dipolar cycloadditions, and Staudinger ligations for conjugating biomolecules using click chemistry
    Patent number: 11639342
    Abstract: Compositions, methods, and kits for the labeling, detecting, isolating and/or analysis of biomolecules modified by attachment of chemical handles are disclosed.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: May 2, 2023
    Assignee: BIOCONJUGATE TECHNOLOGIES, LLC
    Inventors: Andrei Polukhtin, Peter J. An, Alexandra Kulyashova, Jakub M. Labedz, Valentin A. Rassadin, Nikita V. Savelyev, Kostiantyn Ziabrev
  • Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
    Patent number: 11639350
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject, and the compound has the structure of Formula I including any possible deuterated isomers, stereoisomers or tautomeric forms thereof.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 2, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhao-Kui Wan, Yimin Jiang, Xuedong Dai, Qian Liu, Wing Shun Cheung, Gang Deng, Liqiang Fu
  • Inhibitor of p38 MAP kinase
    Patent number: 11634406
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: April 25, 2023
    Assignee: RESPIVERT LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties
    Patent number: 11634405
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 25, 2023
    Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
  • Organic electroluminescent element and novel iridium complex
    Patent number: 11631825
    Abstract: An iridium complex which has a phenylpyridine bidentate ligand containing a group represented by the following general formula (A): wherein X represents a cyano group or a halogenated alkyl group; L represents a single bond or a divalent linking group; R represents a substituent; n represents an integer of 0 to 4; * represents a binding site to a phenylpyridine bidentate ligand.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: April 18, 2023
    Assignee: UDC IRELAND LIMITED
    Inventors: Kousuke Watanabe, Yuichirou Itai
  • Uracil compound as c-MET/AXL inhibitor
    Patent number: 11623923
    Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: April 11, 2023
    Assignee: MEDSHINE DISCOVERY, INC.
    Inventors: Jinping Li, Xiongbin Xu, Gang Li, Lihong Hu, Charles Z. Ding, Yaling Zhou, Guoping Hu, Jian Li, Shuhui Chen
  • Enzyme inhibitors
    Patent number: 11613527
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 28, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
  • Heterocyclic compounds as immunomodulators
    Patent number: 11608337
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • Pyrazole derivatives for the treatment of cystic fibrosis
    Patent number: 11597723
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 7, 2023
    Assignees: Fondazione Istituto Italiano Di Technologia, Istituto Giannina Gasiini, FondaZione Per La Ricerca Sulla Fibrosi Cristica—Onlus
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Heterocyclic compound, application thereof and pharmaceutical composition comprising same
    Patent number: 11591342
    Abstract: Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 28, 2023
    Assignee: SUZHOU SINOVENT PHARMACEUTICALS CO., LTD.
    Inventors: Yonghan Hu, Dongdong Wu, Wei Peng, Xin Li, Fan Hu, Bin Huang, Jinlian Zhu, Yuchuan Wu
  • Porphyrin compounds and compositions useful for treating cancer
    Patent number: 11590233
    Abstract: A porphyrin compound of Formula III and composition made therefrom comprising a therapeutically effective dose of a porphyrin bound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: February 28, 2023
    Assignee: ONCOSELECT THERAPEUTICS, LLC
    Inventors: Maria Zannes, Vivienne I. Rebel, William E. Bauta